Clonixinato de lisina injetável intravenoso para o tratamento agudo das enxaquecas: um estudo piloto aberto

Krymchantowski, Abouch Valenty; Barbosa, Jackeline Soraya

doi:10.1590/s0004-282x1999000400011

Cited by 5 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors have not observed any significant side effects using LC, although nausea, vomiting, allergic reactions, postural hypotension, vertigo and insomnia have been described in the literature 8,9,13 .…”

Section: Discussionmentioning

confidence: 82%

“…The efficacy of other NSAIDs in the acute treatment of migraine, as well as that of lysine clonixinate, have been demonstrated in previous studies [5][6][7][8][9] . This study confirms the efficacy of lysine clonixinate compared to placebo in reducing both intensity and duration of moderate migraine attacks, as well as the consumption of rescue medications after 4 hours.…”

Section: Discussionmentioning

confidence: 99%

“…It has a chemical structure resembling the flufenamic acid, although it is derived from nicotinic acid. Its efficacy in the treatment of acute migraine attacks was suggested by previous non-controlled studies, both in oral 8 as well as in parenteral administration 9 . Lysines structural formula as 2-(3-chloro-o-toluidine)piridino-3-carboxilate allows a fast absorption 10 and its inhibiting effect on the enzyme cyclooxygenase, important in prostaglandin synthesis, is reversible.…”

mentioning

confidence: 92%

See 2 more Smart Citations

Oral lysine clonixinate in the acute treatment of migraine: a double-blind placebo-controlled study

Krymchantowski

Barbosa

Cheim

et al. 2001

Arq. Neuro-Psiquiatr.

Self Cite

View full text Add to dashboard Cite

Several oral nonsteroidal anti-inflammatory drugs (NSAIDs) are effective to treat migraine attacks. Lysine clonixinate (LC) is a NSAID derived from nicotinic acid that has proven to be effective in various pain syndromes such as renal colic and muscular pain. The aim of this double-blind, placebo-controlled study was to evaluate the efficacy of oral LC compared to placebo in the acute treatment of migraine. Sixty four patients with the diagnosis of migraine, according to the IHS criteria, were studied prospectively. Patients received LC or placebo once the headache reached moderate or severe intensity for 6 consecutive attacks. With regard to the moderate attacks, LC was superior than placebo after 1, 2 and 4 hours. The consumption of other rescue medications after 4 hours was significantly higher in the placebo group. With regard to the severe attacks, there was no difference between the active drug group and the placebo group concerning headache intensity and consumption of other rescue medications. We conclude that the NSAID lysine clonixinate is effective in treating moderately severe migraine attacks. It is not superior than placebo in treating severe migraine attacks.

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 92%

See 1 more Smart Citation

Oral lysine clonixinate in the acute treatment of migraine: a double-blind placebo-controlled study

Krymchantowski

Barbosa

Cheim

et al. 2001

Arq. Neuro-Psiquiatr.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, the serotonin release from platelets is inhibited and a central pharmacological action, specifically in thalamus and spinal cord, was demonstrated as well. LC also interacts directly with the central serotonergic system and indirectly with opioid receptor systems in thalamic nuclei, gyrus dentate, and layers of parietal cortex of rats 6,17,20,30 .…”

Section: Discussionmentioning

confidence: 99%

“…Lysine clonixinate (LC) is an anthranilic derivative resembling the chemical structure of the flufenamic acid 15,16 . LC was already suggested for the acute treatment of migraine in controlled and in open trials [15][16][17] . Its structural formula (2-(3-chloro-o-toluidine) piridino-3-carboxilate) allows a fast absorption.…”

mentioning

confidence: 99%

Lysine clonixinate versus dipyrone (metamizole) for the acute treatment of severe migraine attacks: a single-blind, randomized study

Krymchantowski¹,

Carneiro

Barbosa³

et al. 2008

Arq. Neuro-Psiquiatr.

Self Cite

View full text Add to dashboard Cite

-Background and Objective: Nonsteroidal anti-inflammatory drugs (NSAID) are effective to treat migraine attacks. Lysine clonixinate (LC) and dipyrone (metamizol) have been proven effective to treat acute migraine. The aim of this study was to evaluate the efficacy and tolerability of the intravenous formulations of LC and dipyrone in the treatment of severe migraine attacks. Method: Thirty patients (28 women, 2 men), aged 18 to 48 years with migraine according the International Headache Society (IHS) (2004) were studied. The patients were randomized into 2 groups when presenting to an emergency department with a severe migraine attack. The study was single-blind. Headache intensity, nausea, photophobia and side effects were evaluated at 0, 30, 60 and 90 minutes after the drug administration. Rectal indomethacin as rescue medication (RM) was available after 2 hours and its use compared between groups. Results: All patients completed the study. At 30 minutes, 0% of the dipyrone group 13% of the LC group were pain free (p=0.46). At 60 and 90 minutes, 2 (13%) and 5 (33%) patients from the dipyrone group and 11 (73%) and 13 (86.7%) patients from the LC group were pain free (p<0.001). At 60 minutes, significantly more patients from the LC group were nausea-free (p<0.001). Regarding photophobia, there were no differences between groups at 60 minutes (p=0.11). The use of RM at 2 hours did not differ among groups (p=0.50). Pain in the site of the injection was reported by more patients of the LC group compared to the dipyrone group (p<0.0001). Conclusion: LC is significantly superior to dipyrone in treating severe migraine attacks. LC promotes significantly more burning at the site of the injection.Key woRDS: lysine clonixinate, dipyrone (metamizole), migraine, severe attacks, acute treatment. Clonixinato de lisina versus dipirona (metamizol) para o tratamento agudo de uma crise intensa de enxaqueca: estudo monocego e randomizadoResumo -Contexto e Objetivo: Antiinflamatórios não esteroidais (AINe) são eficazes no tratamento de crises de enxaqueca. o objetivo deste estudo foi comparar a eficácia e a tolerabilidade das apresentações injetáveis do clonixinato de lisina (CL) e da dipirona no tratamento de crises intensas de enxaqueca. Método: Trinta pacientes (28 mulheres, 2 homens), com idades entre 18 e 48 anos e enxaqueca de acordo com a Classificação Internacional de Cefaléias (2004) foram estudados. os pacientes foram randomizados em 2 grupos ao se apresentarem em uma unidade de emergência, com uma crise intensa de enxaqueca. o desenho do estudo foi monocego. A intensidade da cefaléia, a presença de náusea e fotofobia e os efeitos colaterais foram avaliados e comparados na administração das drogas e após 30, 60 e 90 minutos. Indometacina retal foi disponibilizada como droga de resgate (DR) e seu uso comparado entre os grupos. Resultados: Todos os pacientes completaram o estudo. Após 30 minutos, 0% do grupo da dipirona e 13% do CL encontravam-se sem cefaléia (p=0,46). Após 60 e 90 minutos, 2 (13%) e 5 (33%) do g...

show abstract

Intravenous lysine clonixinate for the acute treatment of severe migraine attacks: a double-blind, randomized, placebo-controlled study

Krymchantowski

Silva

2003

Current Therapeutic Research

View full text Add to dashboard Cite

show abstract

Clonixinato de lisina injetável intravenoso para o tratamento agudo das enxaquecas: um estudo piloto aberto

Cited by 5 publications

References 8 publications

Oral lysine clonixinate in the acute treatment of migraine: a double-blind placebo-controlled study

Oral lysine clonixinate in the acute treatment of migraine: a double-blind placebo-controlled study

Lysine clonixinate versus dipyrone (metamizole) for the acute treatment of severe migraine attacks: a single-blind, randomized study

Intravenous lysine clonixinate for the acute treatment of severe migraine attacks: a double-blind, randomized, placebo-controlled study

Contact Info

Product

Resources

About